Researchers pave the way to protein therapy in humans

September 03, 1999

St. Louis, Sept. 3, 1999--For decades, pharmaceutical companies have struggled to overcome the molecular equivalent of the Great Wall of China: the outer membrane of cells, which prevents all but the tiniest of proteins from entering. Now researchers have slipped a protein that's more than 200 times larger than the average drug into the cells of living mice and shown that the protein functions.

"For the very first time, we've introduced a large, biologically active protein into every cell of the body-- including cells in the brain that are normally protected by the blood-brain barrier," says Steven F. Dowdy, Ph.D., who led the research team at Washington University School of Medicine in St. Louis. The group published its results in today's issue of Science.

Dowdy is an assistant investigator of the Howard Hughes Medical Institute and an assistant professor of pathology and medicine. Steven R. Schwarze, Ph.D., a postdoctoral fellow in his laboratory, was lead author of the paper.

Getting full-sized, therapeutic proteins into cells would be advantageous because smaller drugs tend to interact with unintended targets. Larger proteins fit only onto the molecules for which they were designed, so they could be given in substantially lower doses, resulting in fewer side effects.

Dowdy led a previous research team that used test-tube experiments to smuggle an enzyme into HIV-infected cells. The results, reported in Nature Medicine last December and January focused on a human enzyme that makes cells self-destruct. The enzyme was modified to include a string of 11 amino acids that served as a passport for crossing a cell's outer membrane. But the researchers needed to prove that large proteins could slip into cells in model animals before considering human applications.

In the Science study, Dowdy and fellow investigators first attached a molecular passport known as a protein transduction domain (PTD) to a compound whose uptake by cells could be monitored. The compound was a dye called fluorescein, which turns green when exposed to fluorescent lighting. It normally doesn't enter cells because of its size-- 2,000 daltons compared with the 500 dalton limit placed on most drugs.

The researchers injected mice with this combined PTD-fluorescein protein and isolated cells from the animals' blood and spleen. All the cells fluoresced green when checked 20 minutes after the injection. Cells in muscle and brain tissue also had soaked up the combined protein. "It was very encouraging to discover that we could get a mouse with an entirely green brain," Dowdy says, noting that the blood-brain barrier, a layer of cells lining the brain's blood vessels, normally prevents most proteins from entering.

Dowdy and colleagues then linked a bacterial enzyme to the PTD and fluorescein. Their fluorescent analysis revealed that the 120,000 dalton enzyme, beta-galactosidase, entered all the cell types tested.

Beta-galactosidase was chosen because its activity could reveal whether an enzyme could continue to function after it had been transported into cells by the PTD. Cells take up proteins better if they are at least partially unfoled, as was true for the enzyme.

Dowdy's team tested whether beta-galactosidase trapped inside cells of injected mice converted the enzyme's clear chemical target into a blue dye. A vibrant blue image of the kidney of the first mouse tissue they evaluated is pinned on a bulletin board above Dowdy's desk. "Once we got this first result, we realized that the protein would be biologically active in the rest of the body," Dowdy says.

The liver, lung, and other tissues of the injected mice also turned blue when exposed to the enzyme's target. The animals' entire brains also stained blue within four hours of injection, indicating that a lot of the bacterial enzyme had refolded there by then. Importantly, the PTD didn't work its magic in the brain by destroying the blood-brain barrier. And the animals had no visible behavioral changes or other differences compared with untreated mice.

Dowdy has since tested modified versions of the PTD that should allow proteins to enter brain cells and other cells even more rapidly. And he is using his new technology to determine whether a malfunctioning protein helps jump-start cancer.

He notes that the laboratory's protein-targeting technology also may enable companies to create drugs that act only in disease-related cells, opening up a completely novel avenue of therapeutic approaches. "We can now do things in normal cells of mice that you could never even dream of doing with any reliability a year ago," Dowdy says.
-end-
GRAPHIC: Image of mouse brain tissue showing active beta-galactosidase available upon request.

Schwarze SR, Ho A, Vocero-Akbani A, Dowdy SF. In Vivo Protein Transduction: Delivery of a Biologically Active Protein into the Mouse. Science, 285, 1569-1572. Sept. 3, 1999.

This research was supported by the Howard Hughes Medical Institute and the National Institutes of Health.

The technology from Dowdy's laboratory has been licensed to IDUN Pharmaceuticals of La Jolla, Calif., and Life Technologies of Rockville, Md.

Washington University School of Medicine

Related Brain Articles from Brightsurf:

Glioblastoma nanomedicine crosses into brain in mice, eradicates recurring brain cancer
A new synthetic protein nanoparticle capable of slipping past the nearly impermeable blood-brain barrier in mice could deliver cancer-killing drugs directly to malignant brain tumors, new research from the University of Michigan shows.

Children with asymptomatic brain bleeds as newborns show normal brain development at age 2
A study by UNC researchers finds that neurodevelopmental scores and gray matter volumes at age two years did not differ between children who had MRI-confirmed asymptomatic subdural hemorrhages when they were neonates, compared to children with no history of subdural hemorrhage.

New model of human brain 'conversations' could inform research on brain disease, cognition
A team of Indiana University neuroscientists has built a new model of human brain networks that sheds light on how the brain functions.

Human brain size gene triggers bigger brain in monkeys
Dresden and Japanese researchers show that a human-specific gene causes a larger neocortex in the common marmoset, a non-human primate.

Unique insight into development of the human brain: Model of the early embryonic brain
Stem cell researchers from the University of Copenhagen have designed a model of an early embryonic brain.

An optical brain-to-brain interface supports information exchange for locomotion control
Chinese researchers established an optical BtBI that supports rapid information transmission for precise locomotion control, thus providing a proof-of-principle demonstration of fast BtBI for real-time behavioral control.

Transplanting human nerve cells into a mouse brain reveals how they wire into brain circuits
A team of researchers led by Pierre Vanderhaeghen and Vincent Bonin (VIB-KU Leuven, Université libre de Bruxelles and NERF) showed how human nerve cells can develop at their own pace, and form highly precise connections with the surrounding mouse brain cells.

Brain scans reveal how the human brain compensates when one hemisphere is removed
Researchers studying six adults who had one of their brain hemispheres removed during childhood to reduce epileptic seizures found that the remaining half of the brain formed unusually strong connections between different functional brain networks, which potentially help the body to function as if the brain were intact.

Alcohol byproduct contributes to brain chemistry changes in specific brain regions
Study of mouse models provides clear implications for new targets to treat alcohol use disorder and fetal alcohol syndrome.

Scientists predict the areas of the brain to stimulate transitions between different brain states
Using a computer model of the brain, Gustavo Deco, director of the Center for Brain and Cognition, and Josephine Cruzat, a member of his team, together with a group of international collaborators, have developed an innovative method published in Proceedings of the National Academy of Sciences on Sept.

Read More: Brain News and Brain Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.